Gland Pharma Limited Latest Updates with Discussion

Q1 FY27 Financial Performance & Core Injectables Growth In August 2026, Gland Pharma announced its financial results for the first quarter ended June 30, 2026 (Q1 FY27). Consolidated revenue from operations grew 16% year-on-year to ₹1,625 crore, anchored by volume growth in core markets (US, Europe, Canada, and Australia). Consolidated net profit (PAT) rose 12.5% YoY to ₹218 crore, while operating EBITDA came in at ₹338 crore with an EBITDA margin of ~21%, supported by steady pricing realizations and base injectable supplies. US FDA Regulatory Compliance & Facility Clearances The company received an Establishment Inspection Report (EIR) from the US FDA for its finished formulation facility at Pashamylaram, Hyderabad, formally concluding the prior inspection with a Voluntary Action Indicated (VAI) status. The Dundigal manufacturing campus also maintained active cGMP compliance status, ensuring unhindered regulatory approvals and commercial supply continuity for generic injectable applications filed with the US regulator. Turnaround Progress at European Subsidiary Cenexi At its European CDMO subsidiary Cenexi, operational throughput showed sequential stabilization following targeted cost rationalization and capacity debottlenecking across its French and Belgian manufacturing sites. The operational integration helped reduce cash burn and narrowed EBITDA drag on Gland Pharma’s consolidated financials, supported by contract renegotiations and new commercial batch manufacturing agreements in sterile liquids and ampoules. ANDA Approvals & Complex Injectable Pipeline Expansion During the quarter, Gland Pharma, along with its marketing partners, secured 5 new Abbreviated New Drug Application (ANDA) approvals from the US FDA and filed 3 fresh ANDAs, focusing on complex injectables, peptides, and lyophilized vials.